Refine by
Intravenous Delivery Suppliers & Manufacturers
5 companies found
based inMelbourne, AUSTRALIA
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care. ...
MPC-300-IV is being developed for the treatment of diabetic complications, including diabetic kidney disease known as diabetic ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Milrinone is a PDE3 inhibitor, and also an inotrope and ...
based inAthlone, IRELAND
The first laryngeal mask airway, the LMA Classic™, was invented and designed by Dr. Archie Brain in the East End of London in 1981. While a practicing anesthesiologist, Dr. Brain identified the need for better safety, reliability, and ease of ...
The MADgic™ Laryngo-Tracheal Mucosal Atomization Device from Teleflex offers a versatile choice to administer topical anesthesia across the entire upper airway and beyond the vocal cords. This helps to suppress the airway responses to ...
based inSuwanee, GEORGIA (US) (USA)
The only all metal syringe infusion pump created in 2008 and made in the USA. Headquartered in Suwanee, Georgia, Atlanta BioMedical was founded in 2008 by industry veterans William (Bill) Arthur III, Charles Lee, and Julius Stempfle to bring the ...
Along with enteral feeding, Atlanta BioMedical Corporation manufactures a dedicated Anesthesia OR pump. The pump recognizes all IV syringe manufacturers and accepts all sizes from 1mL to 140 mL. The pump is made out of metal (not plastic) for ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
Our clinically validated T-SIGn® viral vector platform delivers multiple transgene payloads that re-program the tumor microenvironment of both primary and metastatic tumors. Our platform can integrate rationally designed synthetic agents to ...